University of Texas Southwestern Medical Center
The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ability to modify urinary parameters associated with stone formation.
Kidney stones are a common medical problem, occurring in almost 10% of people in the United States1. Furthermore, 50% of patients will recur within 10 years2. Metabolic testing is advised in recurrent stone formers, as well as those considered high risk, to assess for a specific abnormality which may prompt intervention to prevent future stone formation. Non-surgical interventions include both dietary counselling, as well as pharmacotherapy. One of the most commonly prescribed class of pharmacotherapies is alkali therapy which can be used to both increase the urinary pH and raise the urine ci…
Inclusion Criteria: * Adults aged 18 and older. * with or without a history of stone disease. Exclusion Criteria: * They are unable to take any of the medications due to health reasons. * Participants are pregnant or nursing. * Participants are unable to adhere to the metabolic diet. * Participants had a prior adverse event from one or more of the medications.
Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.
650mg tabs. Take 3 tabs twice daily.
One packet is taken with 170ml of water. Two packets daily.
The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.
20 mEq tablets, one tablet twice daily
Arctuva estimate
Verify or correct the compensation shown for this listing.